恒瑞医药注射用SHR-1826纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the National Medical Products Administration's list of breakthrough therapies, targeting a specific type of lung cancer [1] Group 1 - The indication for SHR-1826 is for monotherapy in patients with locally advanced or metastatic non-squamous non-small cell lung cancer who have previously failed at least one line of systemic therapy [1] - The targeted patient population has c-Met overexpression (2-3+, ≥50%) [1]